ERAS Stock Analysis: Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors
- Latest close
- $14.74
- 20-day change
- -9.35%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Erasca, Inc. moved -9.35% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · -$124.5M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.8/6, while Value is the lowest at 1.0/6. Scores are comparative research signals, not forecasts.